Deallus

Deallus

Healthcare and life sciences consulting

Overview

Deallus provides consulting services for the life sciences and healthcare sectors. It helps pharmaceutical, biotechnology, medical device, and healthcare companies with research-driven strategic support, including competitive intelligence, market analyses, pipeline and product strategy, and due diligence for mergers, partnerships, or investments. Its offerings translate scientific and market data into actionable insights through customized reports, dashboards, and advisory services. What sets Deallus apart is its focus on life sciences and health care, combining deep scientific understanding with intelligence and strategy work to deliver targeted, decision-ready analysis. The company aims to help clients make informed, faster decisions to maximize value in drug development, commercialization, and healthcare products.

About Deallus

Simplify's Rating
Why Deallus is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Consulting

Biotechnology

Healthcare

Company Size

1-10

Company Stage

N/A

Total Funding

N/A

Headquarters

London, United Kingdom

Founded

2012

Get referred to Deallus

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • GlobalData completed the Deallus acquisition on 31 December 2024, adding stronger distribution.
  • Deallus now sells into GlobalData Healthcare’s broader life-sciences client base worldwide.
  • Demand for competitive readiness remains explicit on Deallus’s site, supporting recurring advisory work.

What critics are saying

  • Peter Hempshall resigned as Deallus director on 20 January 2026, weakening continuity.
  • GlobalData’s January 2025 acquisition logic folds Deallus into a larger platform, diluting brand autonomy.
  • If GlobalData prioritizes bundled data subscriptions, Deallus’s expert consulting becomes a commoditized add-on.

What makes Deallus unique

  • Deallus spent 20 years specializing in life-sciences competitive intelligence, per 2025 GlobalData release.
  • Its therapy-depth spans oncology, neuroscience, vaccines, rare diseases, cell and gene, immunology.
  • GlobalData bought Deallus on 31 December 2024, signaling premium strategic intelligence quality.

Help us improve and share your feedback! Did you find this helpful?

Recently Posted Jobs

Sign up to get curated job recommendations

Deallus is Hiring for 4 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →